About Lorus Therapeutics (NASDAQ:APTO)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828
Debt
Debt-to-Equity RatioN/A
Current Ratio6.72%
Quick Ratio6.72%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book8.74
Profitability
EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-123.32%
Return on Assets-106.81%
Miscellaneous
Employees23
Outstanding Shares30,700,000
Lorus Therapeutics (NASDAQ:APTO) Frequently Asked Questions
What is Lorus Therapeutics' stock symbol?
Lorus Therapeutics trades on the NASDAQ under the ticker symbol "APTO."
How were Lorus Therapeutics' earnings last quarter?
Lorus Therapeutics, Inc. (NASDAQ:APTO) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.07. View Lorus Therapeutics' Earnings History.
What price target have analysts set for APTO?
4 Wall Street analysts have issued 1 year price objectives for Lorus Therapeutics' shares. Their predictions range from $6.00 to $7.00. On average, they expect Lorus Therapeutics' stock price to reach $6.3333 in the next year. View Analyst Ratings for Lorus Therapeutics.
Who are some of Lorus Therapeutics' key competitors?
Some companies that are related to Lorus Therapeutics include Compugen (CGEN), Pluristem Therapeutics (PSTI), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Aevi Genomic Medicine (GNMX), Curis (CRIS), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Vaxart (VXRT), Proteon Therapeutics (PRTO), Microbot Medical (MBOT), Vical (VICL) and Neuralstem (CUR).
Who are Lorus Therapeutics' key executives?
Lorus Therapeutics' management team includes the folowing people:
- Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
- Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
- Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
- Mr. Peter Murray, Director of Clinical Devel.
Has Lorus Therapeutics been receiving favorable news coverage?
Media coverage about APTO stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lorus Therapeutics earned a news impact score of 0.07 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Lorus Therapeutics?
Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lorus Therapeutics' stock price today?
One share of APTO stock can currently be purchased for approximately $3.41.
How big of a company is Lorus Therapeutics?
Lorus Therapeutics has a market capitalization of $104.69 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Lorus Therapeutics employs 23 workers across the globe.
How can I contact Lorus Therapeutics?
Lorus Therapeutics' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]
MarketBeat Community Rating for Lorus Therapeutics (APTO)
MarketBeat's community ratings are surveys of what our community members think about Lorus Therapeutics and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Lorus Therapeutics (NASDAQ:APTO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Lorus Therapeutics in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 85.73%. The high price target for APTO is $7.00 and the low price target for APTO is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.3333 | $6.00 | $6.00 | $7.00 |
| Price Target Upside: | 85.73% upside | 86.92% upside | 233.33% upside | 389.51% upside |
Lorus Therapeutics (NASDAQ:APTO) Consensus Price Target History
Lorus Therapeutics (NASDAQ:APTO) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Lorus Therapeutics (NASDAQ:APTO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Lorus Therapeutics (NASDAQ APTO) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 1.17%
Lorus Therapeutics (NASDAQ APTO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Lorus Therapeutics (NASDAQ APTO) News Headlines
| Source: |
|
Lorus Therapeutics (NASDAQ:APTO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Lorus Therapeutics (NASDAQ:APTO) Income Statement, Balance Sheet and Cash Flow Statement
Lorus Therapeutics (NASDAQ APTO) Stock Chart for Sunday, April, 22, 2018
Loading chart…
